NYSE:GSK - GlaxoSmithKline Stock Price, News, Headlines & Rumors

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GlaxoSmithKline announced a quarterly dividend on Wednesday, July 25th. Shareholders of record on Friday, August 10th will be given a dividend of $0.496 per share on Thursday, October 11th. This represents a $1.98 dividend on an annualized basis and a yield of 4.86%. The ex-dividend date is Thursday, August 9th. View GlaxoSmithKline's Dividend History.

GlaxoSmithKline plc (NYSE:GSK) issued its quarterly earnings results on Wednesday, July, 25th. The pharmaceutical company reported $0.77 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.71 by $0.06. The pharmaceutical company had revenue of $9.95 billion for the quarter, compared to analysts' expectations of $9.47 billion. GlaxoSmithKline had a return on equity of 159.74% and a net margin of 5.51%. View GlaxoSmithKline's Earnings History.

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, October, 24th 2018. View Earnings Estimates for GlaxoSmithKline.

13 analysts have issued 12 month target prices for GlaxoSmithKline's shares. Their forecasts range from $35.85 to $40.00. On average, they expect GlaxoSmithKline's stock price to reach $38.9625 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for GlaxoSmithKline.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News coverage about GSK stock has been trending somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlaxoSmithKline earned a coverage optimism score of 0.24 on Accern's scale. They also assigned media stories about the pharmaceutical company an impact score of 48.16 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for GlaxoSmithKline.

GlaxoSmithKline's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (0.76%), Fisher Asset Management LLC (0.56%), Renaissance Technologies LLC (0.38%), Bank of America Corp DE (0.31%), Bank of New York Mellon Corp (0.24%) and Federated Investors Inc. PA (0.18%). View Institutional Ownership Trends for GlaxoSmithKline.

GSK stock was sold by a variety of institutional investors in the last quarter, including OLD Republic International Corp, Connor Clark & Lunn Investment Management Ltd., FMR LLC, Confluence Investment Management LLC, Chartwell Investment Partners LLC, Bruderman Asset Management LLC, Anchor Capital Advisors LLC and Ariel Investments LLC. View Insider Buying and Selling for GlaxoSmithKline.

GSK stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, South Texas Money Management Ltd., Fisher Asset Management LLC, Cornerstone Wealth Management LLC, BlackRock Inc., Bank of New York Mellon Corp and Canada Pension Plan Investment Board. View Insider Buying and Selling for GlaxoSmithKline.

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GSK stock can currently be purchased for approximately $40.83.

GlaxoSmithKline has a market capitalization of $99.57 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]